PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosis

Translational Psychiatry

Volumn 2, Issue , 2012, Pages

  Wiescholleck, V ^a,b   Manahan Vaughan, D ^a,b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

In vivo; Long term potentiation; MK801; PDE4 inhibition; Rolipram; Schizophrenia

Indexed keywords

PHOSPHODIESTERASE IV; ROLIPRAM; CYCLIC AMP; DIZOCILPINE MALEATE; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; PHOSPHODIESTERASE IV INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENTATE GYRUS; ENZYME INHIBITION; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; LONG TERM POTENTIATION; MALE; MEMORY; NERVE CELL PLASTICITY; NONHUMAN; PSYCHOSIS; RAT; RECOGNITION; SHORT TERM POTENTIATION; SYNAPTIC POTENTIAL; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; PATHOPHYSIOLOGY; PATTERN RECOGNITION; PHYSIOLOGY; RECALL; SUBCUTANEOUS DRUG ADMINISTRATION; SYNAPSE; SYNAPTIC TRANSMISSION; WISTAR RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CYCLIC AMP; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SUBCUTANEOUS; LONG-TERM POTENTIATION; MALE; MENTAL RECALL; NEURONAL PLASTICITY; NEUROPROTECTIVE AGENTS; PATTERN RECOGNITION, VISUAL; PHOSPHODIESTERASE 4 INHIBITORS; PSYCHOTIC DISORDERS; RATS; RATS, WISTAR; ROLIPRAM; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 84858031316     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2012.17     Document Type: Article

References (61)

1. Rutten K, Prickaerts J, Schaenzle G, Rosenbrock H, Blokland A. Sub-chronic rolipram treatment leads to a persistent improvement in long-term object memory in rats. Neurobiol Learn Mem 2008; 90: 569-575.
2. Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci USA 1998; 95: 15020-15025. (Pubitemid 29003749)
3. van Staveren WC, Markerink-van Ittersum M, Steinbusch HW, de Vente J. The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat. Brain Res 2001; 888: 275-286. (Pubitemid 32058793)
4. Waltereit R, Weller M. Signaling from cAMP/PKA to MAPK and synaptic plasticity. Mol Neurobiol 2003; 27: 99-106. (Pubitemid 36515162)
5. Barco A, Pittenger C, Kandel ER. CREB, memory enhancement and the treatment of memory disorders: promises, pitfalls and prospects. Expert Opin Ther Targets 2003; 7: 101-114. (Pubitemid 36204592)
6. Navakkode S, Sajikumar S, Frey JU. The type IV-specific phosphodiesterase inhibitor rolipram and its effect on hippocampal long-term potentiation and synaptic tagging. J Neurosci 2004; 24: 7740-7744. (Pubitemid 39186829)
7. Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol 1973; 232: 331-356.
8. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993; 361: 31-39. (Pubitemid 23020772)
9. Kemp A, Manahan-Vaughan D. Hippocampal long-term depression: master or minion in declarative memory processes? Trends Neurosci 2007; 30: 111-118.
10. Douki S, Taktak MJ, Ben Zineb S, Cheour M. Therapeutic strategies in the first psychotic episode. Encephale 1999; 25(Spec No 3): 44-51.
11. McGorry PD, Killackey E, Yung A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry 2008; 7: 148-156.
12. Goldner-Vukov M, Cupina DD, Moore LJ, Baba-Milkiæ N, Milovanoviæ S. Early intervention in first episode psychosis: hope for a better future. Srp Arh Celok Lek 2007; 135: 672-678.
13. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 1998; 172: 53-59. (Pubitemid 28258899)
14. Bird V, Premkumar P, Kendall T, Whittington C, Mitchell J, Kuipers E. Early intervention services, cognitive-behavioural therapy and family intervention in early psychosis: systematic review. Br J Psychiatry 2010; 197: 350-356.
15. Wöhrl R, Eisenach S, Manahan-Vaughan D, Heinemann U, von Haebler D. Acute and long-term effects of MK-801 on direct cortical input evoked homosynaptic and heterosynaptic plasticity in the CA1 region of the female rat. Eur J Neurosci 2007; 26: 2873-2883. (Pubitemid 350115513)
16. Manahan-Vaughan D, von Haebler D, Winter C, Juckel G, Heinemann U. A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats. Hippocampus 2008; 18: 125-134. (Pubitemid 351413480)
17. Manahan-Vaughan D, Wildförster V, Thomsen C. Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1). Eur J Neurosci 2008; 28: 1342-1350.
18. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001; 25: 455-467. (Pubitemid 32830950)
19. Tamminga CA, Holcomb HH, Gao XM, Lahti AC. Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. Int Clin Psychopharmacol 1995; 10(Suppl 3): 29-37. (Pubitemid 26054878)
20. Davis JA, Gould TJ. Rolipram attenuates MK-801-induced deficits in latent inhibition. Behav Neurosci 2005; 119: 595-602. (Pubitemid 40547964)
21. Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 2007; 144: 239-246. (Pubitemid 44839057)
22. Millar JK, Mackie S, Clapcote SJ, Murdoch H, Pickard BS, Christie S et al. Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness. J Physiol 2007; 584(Pt 2): 401-405. (Pubitemid 47578327)
23. Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 2005; 310: 1187-1191. (Pubitemid 41681745)
24. Blackwood DH, Fordyce A, Walker MT, St Clair DM, Porteous DJ, Muir WJ. Schizophrenia and affective disorders-cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet 2001; 69: 428-433. (Pubitemid 32695214)
25. Sachs NA, Sawa A, Holmes SE, Ross CA, DeLisi LE, Margolis RL. A frameshift mutation in Disrupted in Schizophrenia 1 in an American family with schizophrenia and schizoaffective disorder. Mol Psychiatry 2005; 10: 758-764. (Pubitemid 41129048)
26. Sawa A, Snyder SH. Genetics. Two genes link two distinct psychoses. Science 2005; 310: 1128-1129. (Pubitemid 41681728)
27. Mackie S, Millar JK, Porteous DJ. Role of DISC1 in neural development and schizophrenia. Curr Opin Neurobiol 2007; 17: 95-102. (Pubitemid 46227982)
28. Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, O'Donnell JM. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology 2000; 23: 198-204. (Pubitemid 30406904)
29. Siuciak JA, Chapin DS, McCarthy SA, Martin AN. Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology 2007; 192: 415-424. (Pubitemid 46701580)
30. Manahan-Vaughan D, Braunewell KH, Reymann KG. Subtype-specific involvement of metabotropic glutamate receptors in two forms of long-term potentiation in the dentate gyrus of freely moving rats. Neuroscience 1998; 86: 709-721. (Pubitemid 28298730)
31. Romón T, Mengod G, Adell A. Expression of parvalbumin and glutamic acid decarboxylase-67 after acute administration of MK-801. Implications for the NMDA hypofunction model of schizophrenia. Psychopharmacology 2011; 217: 231-238.
32. Steiner AL, Parker CW, Kipnis DM. Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. J Biol Chem 1972; 247: 1106-1113.
33. Harper JF, Brooker G. Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 200 acetylation by acetic anhydride in aqueous solution. J Cyclic Nucleotide Res 1975; 1: 207-218.
34. Prickaerts J, de Vente J, Honig W, Steinbusch HWM, Blokland A. cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation. Eur J Pharmacol 2002; 436: 83-87. (Pubitemid 34142401)
35. Navakkode S, Sajikumar S, Frey JU. Mitogen-activated protein kinase-mediated reinforcement of hippocampal early long-term depression by the type IV-specific phosphodiesterase inhibitor rolipram and its effect on synaptic tagging. J Neurosci 2005; 25: 10664-10670. (Pubitemid 41681914)
36. Navakkode S, Korte M. Cooperation between cholinergic and glutamatergic receptors are essential to induce BDNF-dependent long-lasting memory storage. Hippocampus 2011; 22: 335-346, doi: 10.1002/hipo.20902.
37. Sweatt JD. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 2001; 76: 1-10.
38. Beavo JA. Multiple isozymes of cyclic nucleotide phosphodiesterase. Adv. Second Messenger Phosphoprotein Res 1988; 22: 1-38.
39. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006; 58: 488-520. (Pubitemid 44394910)
40. Monti B, Berteotti C, Contestabile A. Subchronic rolipram delivery activates hippocampal CREB and arc, enhances retention and slows down extinction of conditioned fear. Neuropsychopharmacology 2006; 31: 278-286. (Pubitemid 43113393)
41. Li Y, Cheng Y, Huang Y, Conti M, Wilson SP, O'Donnell JM et al. Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling. J Neurosci 2011; 31: 172-183.
42. Rutten K, Basile JL, Prickaerts J, Blokland A, Vivian JA. Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. Psychopharmacology 2008; 196: 643-648.
43. Reneerkens OAH, Rutten K, Steinbusch HWM, Blokland A, Prickaerts J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology 2009; 202: 419-443.
44. Normann C, Berger M. Neuroenhancement: status quo and perspectives. Eur Arch Psychiatry Clin Neurosci 2008; 258(Suppl 5): 110-114.
45. Zeller E, Stief HJ, Pflug B, Sastre-y-Hernández M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 1984; 17: 188-190. (Pubitemid 15213947)
46. Hebenstreit GF, Fellerer K, Fichte K, Fischer G, Geyer N, Meya U et al. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry 1989; 22: 156-160. (Pubitemid 19176094)
47. Halene TB, Siegel SJ. Antipsychotic-like properties of phosphodiesterase 4 inhibitors: evaluation of 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with auditory event-related potentials and prepulse inhibition of startle. J Pharmacol Exp Ther 2008; 326: 230-239. (Pubitemid 351872113)
48. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 2008; 33: 2061-2079. (Pubitemid 351992095)
49. Frey U, Huang YY, Kandel ER. Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. Science 1993; 260: 1661-1664. (Pubitemid 23247151)
50. Krause W, Kühne G. Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences. Xenobiotica 1988; 18: 561-571.
51. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 2004; 114: 1624-1634. (Pubitemid 40385553)
52. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008; 31: 234-242.
53. Gordon JA. Testing the glutamate hypothesis of schizophrenia. Nat Neurosci 2010; 13: 2-4.
54. Jodo E, Suzuki Y, Katayama T, Hoshino K, Takeuchi S, Niwa S et al. Activation of medial prefrontal cortex by phencyclidine is mediated via a hippocampo-prefrontal pathway. Cereb Cortex 2005; 15: 663-669. (Pubitemid 40577482)
55. Rosenmund C, Clements JD, Westbrook GL. Nonuniform probability of glutamate release at a hippocampal synapse. Science 1993; 262: 754-757. (Pubitemid 23350697)
56. Skeberdis VA, Chevaleyre V, Lau CG, Goldberg JH, Pettit DL, Suadicani SO et al. Protein kinase A regulates calcium permeability of NMDA receptors. Nat Neurosci 2006; 9: 501-510.
57. Li B, Devidze N, Barengolts D, Prostak N, Sphicas E, Apicella AJ et al. NMDA receptor phosphorylation at a site affected in schizophrenia controls synaptic and behavioral plasticity. J Neurosci 2009; 29: 11965-11972.
58. Emamian ES, Karayiorgou M, Gogos JA. Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with Schizophrenia. J Neurosci 2004; 24: 1561-1564. (Pubitemid 38240950)
59. Zhang H, Huang Y, Suvarna NU, Deng C, Crissman AM, Hopper AT et al. Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats. Psychopharmacology 2005; 179: 613-619. (Pubitemid 40674762)
60. Suvarna NU, O'Donnell JM. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus. J Pharmacol Exp Ther 2002; 302: 249-256. (Pubitemid 34680445)
61. Rampino A. DISC 2010 - protein with many talents. Schizophrenia Research Forum website, 5 November 2010, accessed 10 April 2011. Available from: http://www.schizophreniaforum.org/new/detail.asp?id=1632.